Skip to Content

CAR-T cell therapy provides early and deep response in multiple myeloma patients

Initial data from the phase II study CARTITUDE-2 show that patients with refractory multiple myeloma received an early and deep response to treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta cell).

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top